There is so much that we don't know about CYP product. I was...

There is so much that we don't know about CYP product. I was really interested in investing since I know some of our members are also holders of CYP. But after having some read on iMSCs (or MSCs derived from iPSCs) that CYP produces, I have concerns over safety and efficacy. Safety in terms of its tendency of having cancer-causing genes¹ and incomplete reprogramming when converting iPSCs to MSCs². Efficacy due to the low conversion rate of iPSCs³ and most recent findings which suggest that IMSCs are actually more similar to VPCs than MSCs⁴. I thought better wait until MSB hit $20 then maybe sell some to gamble on CYP. Best of luck with your investment.


Sources:
1. Kaplan, Karen (6 March 2009). "Cancer threat removed from stem cells, scientists say". Los Angeles Times.
2. Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, et al. (September 2009). "iPS cells produce viable mice through tetraploid complementation". Nature. 461 (7260): 86–90. doi:10.1038/nature08267. PMID 19672241
3. Takahashi, K; Yamanaka, S (August 2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors". Cell. 126 (4): 663–76. doi:10.1016/j.cell.2006.07.024. PMID 16904174
4. Xu, M., Shaw, G., Murphy, M., & Barry, F. (2020). Imprecise lineage definition associates with functional dissimilarity observed between IPSC-derived MSCS and primary MSCs. Cytotherapy, 22(5), S112-S113.